Association Review
In brief The association between TP53 (Tumor Protein P53) and Gallbladder Cancer is supported by expert-curated evidence, drawing on a single expert-curated source, which records pathogenic variants.
Sources
1
Clinical variants
6
Symptoms
8
Compounds
1
Trials
29 of 1,870 via TP53 compounds
Publications
0
Contents
01
At a glance
Association overview A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access 02
Provenance
Evidence and sources 1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access 3 source summaries
A gene summary alongside the source descriptions it was distilled from.
Request access 04
Gallbladder Cancer
The disorder 15 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access 05
ClinVar and variant evidence
Genetic basis 6 clinical variants
ClinVar variants reported for this pair, with disorder-specific significance, review status, molecular consequence and origin.
Request access 06
Population genetics
GWAS signals 1 GWAS phenotype
Gene-associated GWAS phenotypes matching the disorder, with best SNP, score, risk-allele frequency and effect size.
Request access 07
Interventions
Therapeutics 1 compound or drug
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access 08
Human studies
Clinical trials 1,870 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access 09
Provenance
References & sources 8 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access 
